Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Natural History of Stroke: Årsak og utvikling

Evaluering, patogenese og behandling av pasienter med eller i risiko for cerebrovaskulær sykdom (A Natural History/Disease Pathogenesis Protocol)

The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.

Patients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.

The study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:

  • Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests.
  • Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm.
  • Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain.
  • Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.
  • Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck.
  • Echocardiogram-sound waves are used to image the heart and evaluate heart function.

Patients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and/or 12 months, when some of these tests may be repeated to assess changes over time

Studieoversikt

Detaljert beskrivelse

Study Description:

This is a natural history/disease pathogenesis protocol for evaluation of patients with or at risk of acute stroke, transient ischemic attack (TIA), or other disturbances of cerebrovascular circulation. The purpose of this protocol is to generate natural history data to serve as the basis for future hypothesis-driven protocols as well as to contribute to the clinical and physiological understanding of cerebrovascular disease through the description of disease manifestation and the relationship among clinical, hematologic, and radiologic variables, as well as identifying potential subjects for future studies on stroke and other cerebrovascular diseases.

Objectives:

  • To establish a registry of subjects with cerebrovascular disease including clinical, laboratory, and radiological variables associated with hemorrhagic and ischemic stroke, TIA, and other disturbances of cerebrovascular circulation.
  • To characterize the natural history of acute stroke, TIA, and other disturbances of cerebrovascular circulation on these variables.
  • To evaluate the relationship among these variables by exploratory analyses and to generate hypotheses for future testing.
  • To identify potential subjects for research studies on stroke and other cerebrovascular diseases.

Endpoints:

A primary purpose of this observational protocol is to discover and study new imaging biomarkers that are i) relevant to the acute presentation and severity, ii) predictive of clinical outcome, and iii) are useful for stratifying the biological response as reflected in blood-biomarker and gene expression studies. As such, the primary outcome is the results from the imaging studies.

Primary Outcome Measures

Prevalence and type of abnormalities seen on neuroimaging as a function of time from acute insult such as:

  • Imaging positive for acute ischemic cerebral vascular syndrome ( AICS positive )[1]
  • Presence of a lesion on diffusion, perfusion, and mismatch between the two
  • Evidence of a vascular occlusion on MR angiography
  • Evidence of a thrombus or hemorrhage on T2* GRE imaging
  • Blood-brain barrier disruption as evidence by HARM [2]
  • The evolution of these markers with time and treatment

Secondary Outcome Measures

  • Stroke severity as measured by NIHSS as a function of time since index event.
  • Clinical outcome measured using modified Rankin Scale and Barthel Index
  • Gene expression profiles and biomarker levels obtained from blood samples.

Studietype

Observasjonsmessig

Registrering (Antatt)

4000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Rekruttering
        • Medstar Washington Hospital Center
        • Ta kontakt med:
    • Maryland
      • Bethesda, Maryland, Forente stater, 20892
        • Rekruttering
        • National Institutes of Health Clinical Center
        • Ta kontakt med:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • Telefonnummer: TTY dial 711 800-411-1222
          • E-post: ccopr@nih.gov
      • Bethesda, Maryland, Forente stater, 20814
        • Rekruttering
        • Suburban Hospital - Johns Hopkins Medicine
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 120 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Subjects are recruited from the collaborative stroke programs between NINDS and affiliated hospitals (Suburban Hospital and MedStar Washington Hospital Center) and will be followed for the duration of their hospitalization. Select subjects will then be seen for follow up for up to one year.

Beskrivelse

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Aged >=18
  2. Presented to participating study site (ED, ICU, or inpatient unit) with or at risk of acute stroke, TIA, or other disturbances of cerebrovascular circulation

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Subjects with contraindication to MRI scanning will be excluded from any testing which involves the use of MRI. The contraindications include subjects with the following devices or conditions:

    • Central nervous system aneurysm clips
    • Implanted neural stimulator
    • Implanted cardiac pacemaker or defibrillator
    • Cochlear implant
    • Ocular foreign body (e.g. metal shavings)
    • Insulin pump
    • Metal shrapnel or bullet
    • Any implanted device that is incompatible with MRI

    Subjects with a condition precluding entry in the scanner (e.g. morbid obesity, Claustrophobia, etc.) will not be included in the MRI portion of this study.

  2. Pregnancy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Patients

Patients with acute stroke symptoms

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prevalence and type of abnormalities seen on neuroimaging as a function of time from acute insult
Tidsramme: Post-acute, 24 hours, 5 days/discharge, 30 days

Neuroimaging abnormalities, such as:-Imaging positive for acute ischemic cerebral vascular syndrome ( AICS positive )-Presence of a lesion on diffusion, perfusion, and mismatch between the two-Evidence of a vascular occlusion on MR angiography-Evidence of a thrombus or hemorrhage on T2* GRE imaging-Blood-brain barrier disruption as evidence by "HARM"-The evolution of these markers with time and treatment

Post-acute, 24 hours, 5 days/discharge, 30 days

Sekundære resultatmål

Resultatmål
Tidsramme
Alvorlighetsgrad av hjerneslag målt av NIHSS som en funksjon av tiden siden indekshendelse
Tidsramme: Postakutt, 24 timer, 5 dager/utskrivning, 30 dager, 3 måneder, 6 måneder, 12 måneder
Postakutt, 24 timer, 5 dager/utskrivning, 30 dager, 3 måneder, 6 måneder, 12 måneder
Klinisk utfall målt ved hjelp av modifisert Rankin Scale og Barthel Index
Tidsramme: 5 dager/utskrivning, 30 dager, 3 måneder, 6 måneder, 12 måneder
5 dager/utskrivning, 30 dager, 3 måneder, 6 måneder, 12 måneder
Genekspresjonsprofiler og biomarkørnivåer hentet fra blodprøver
Tidsramme: Postakutt, 24 timer, 5 dager/utskrivning, 30 dager, 3 måneder, 6 måneder, 12 måneder
Postakutt, 24 timer, 5 dager/utskrivning, 30 dager, 3 måneder, 6 måneder, 12 måneder

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Lawrence L Latour, Ph.D., National Institute of Neurological Disorders and Stroke (NINDS)

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. januar 2001

Datoer for studieregistrering

Først innsendt

24. januar 2001

Først innsendt som oppfylte QC-kriteriene

24. januar 2001

Først lagt ut (Antatt)

25. januar 2001

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. oktober 2026

Sist bekreftet

14. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Individual Participant Data that underlie the results reported in the publication, after deidentification.

IPD-delingstidsramme

Beginning 3 months and ending 5 years after article publication.

Tilgangskriterier for IPD-deling

IPD will be shared with researchers who provide a methodologically sound proposal . Proposals should be sent to the corresponding author of the publication.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere